The Patent Finder

Terms ending in 2027

Oncotherapy Science, Inc.

Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,053,556GLYPICAN-3 (GPC3)-Derived Tumor Rejection Antigenic Peptides Useful for HLA-A2-POSITIVE Patients and Pharmaceutical Comprising the Same
In force
 · High confidence
Oncotherapy Science, Inc.In forceHigh confidence
US 9,545,437Peptide Vaccines for Cancers Expressing MPHOSPH1 or DEPDC1 Polypeptides
In force
 · Medium confidence
Oncotherapy Science, Inc.In forceMedium confidence
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited